Kincell Bio

Kincell Bio, a cell therapy contract development and manufacturing organization (CDMO) with a Research Triangle Park facility, announced on September 17, 2026…

Combination creates a scaled U.S. advanced therapies CDMO with broader technical expertise and capabilities from early development through commercial supply. RESEARCH TRIANGLE PARK, NC and THE WOODLANDS, TX - Sept. 17, 2026: Kincell Bio and Cellipont Bios

In this exclusive Cell & Gene Therapy Review feature, Darren Head, CEO, and Larry Pitcher, President, share how the combination of Kincell Bio and Cellipont Bioservices came together; and what it means for customers, employees, and the future of the organ

.avia-section.av-7ys3i3-ee6d02775dace9356a4997bb0b594f02{ background-color:#003e6a; background:linear-gradient( to bottom right, #003e6a, #001d32 ); } Advancing Cell Therapy Development with Integrated Analytical and Process Strategies Cell therapy develo

Cell therapy development is defined by a fundamental tension: the pressure to move fast and the imperative to get it right. With many programs receiving expedited approval designations, the need to reach the clinic quickly is real, but so are the conseque

Great science starts with great people. The Kincell Bio team shares what it feels like and what it means to work at a company where collaboration is genuine, leadership is approachable, and every person understands that patients' lives depend on their wor

As cell therapies advance from early development toward commercialization, Chemistry, Manufacturing, and Controls (CMC) strategy has become a critical determinant of regulatory and clinical success. A proactive, evolving CMC roadmap can help sponsors anti

.avia-section.av-7ys3i3-ee6d02775dace9356a4997bb0b594f02{ background-color:#003e6a; background:linear-gradient( to bottom right, #003e6a, #001d32 ); } The Celebration of Kincell Bio's Expanded RTP Facility Join our open house as we officially open our exp

While the curative potential of cell therapies is incredible, the path from a promising candidate in the lab to an approved therapy in the clinic is extraordinarily complex. However, the majority of programs that complete the journey successfully share on